Accreditation Information
Learning Objectives:
At the conclusion of the program, learners will better be able to:
- Evaluate emerging and established therapies in rheumatology care, including their indications, mechanisms of action, and impact on patient outcomes.
- Apply current clinical guidelines and evidence-based recommendations to the diagnosis and management of complex rheumatologic conditions across the lifespan.
- Differentiate between evidence-based, evidence-informed, and real-world clinical practices in rheumatology and discuss their implications for individualized patient care.
- Integrate strategies to optimize multidisciplinary care, resource utilization, and health policy engagement in support of improved patient access and advocacy.
Target Audience:
The target audience for this forum includes registered nurses (RNs), advanced practice providers (APPs), licensed practical and vocational nurses (LPNs/LVNs), and other healthcare professionals who are engaged in clinical practice, education, research, and advocacy for the care of adult and pediatric patients with rheumatic diseases. The content of this education will also be applicable to healthcare professionals new to rheumatology, as well as students considering entering the field of rheumatology.
Evaluation Process:
The online evaluation will be made available on RNSnurse.org at the conclusion of the conference. You will receive an email with instructions on how to log in to the website to complete the online evaluation. Once completed, your Certificate of Credit and Attendance will be calculated and saved to your online profile and will be available to print.
Accreditation:
The Rheumatology Nurses Society is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (Provider No. P0500).
Participants will have the opportunity to receive up to 12.0 ANCC contact hours and 2.0 pharmacotherapeutic hours. Contact hours are awarded commensurate with participation and completing an online assessment upon completion of the program.
Faculty Disclosures:
According to the disclosure policy of the Rheumatology Nurses Society, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence. All relevant financial relationships have been mitigated.
Planners, reviewers, and faculty relevant financial relationship disclosures with ineligible companies are listed below:
| Sadie Larson, Executive Director, Administration Nothing to Disclose |
| Carolyn Zic, MSN, FNP-BC, Accredited Provider Program Director, Faculty Presenter Nothing to Disclose |
| Michelle Bastien, MSN, NP-C, Planning Committee Nothing to Disclose |
| Shelby Jones, MSN, APRN, CPNP-PC, Planning Committee Nothing to disclose |
| Chad Hille, MD, Faculty Presenter Nothing to disclose |
| Sheila Behimehr, MS, APRN, AGNP-C, Faculty Presenter Nothing to disclose |
| Diana Finney, RN, MSc, Faculty Presenter Speaker: UCB, Novartis |
| Louise Parker RN, BSc (Hons), MSc, NIP, Faculty Presenter Nothing to disclose |
| Kimberly Trotter, MD, Faculty Presenter Advisory Board: GSK |
| Polly Livermore, PhD, MSc, BSc (Hons), Faculty Presenter Nothing to disclose |
| Linda Wagner-Weiner, MD, Faculty Presenter Nothing to disclose |
| Helen Smith, APRN, Faculty Presenter Nothing to disclose |
| Monica Parsons, BSN, RN, Faculty Presenter Nothing to disclose |
| Karen McKerihan, MSN, NP-C, Faculty Presenter Advisory Board: Sobi, Amgen, UCB, Novartis Speaker: Amgen |
| Nick Manwaring, MSN, APRN, FNP-C, Faculty Presenter Nothing to disclose |
Educational Supporters: This program has been supported by educational grants from Mallinckrodt Pharmaceuticals and Johnson and Johnson